Ovarian cancer remains one of the leading causes of gynecologic cancer-related mortality worldwide. Although many patients initially respond to platinum-based chemotherapy, the majority eventually develop recurrent disease requiring multiple lines of treatment. The management of recurrent ovarian cancer depends on several factors, including platinum-free interval (PFI), prior therapies, patient performance status, molecular characteristics, cumulative toxicities, and treatment goals.

In this setting, non-platinum therapeutic strategies have become increasingly important, particularly for patients with partially platinum-sensitive recurrence or those requiring postponement of additional platinum exposure.

Trabectedin is a marine-derived antineoplastic agent approved in combination with pegylated liposomal doxorubicin (PLD) for selected patients with recurrent platinum-sensitive ovarian cancer in several regions. Trabectedin possesses a unique mechanism of action involving DNA minor groove binding, modulation of transcription processes, interference with DNA repair pathways, and effects on the tumor microenvironment.

The combination of trabectedin and PLD demonstrated clinically meaningful activity in recurrent ovarian cancer, particularly in patients with partially platinum-sensitive disease, and contributed to the development of platinum-sparing therapeutic strategies.

Classification of Recurrent Ovarian Cancer

Recurrent ovarian cancer is commonly categorized according to the platinum-free interval:

• Platinum-sensitive: recurrence occurring more than 6 months after completion of platinum therapy
• Partially platinum-sensitive: recurrence between 6–12 months after platinum therapy
• Platinum-resistant: recurrence within 6 months
• Platinum-refractory: progression during platinum-based therapy

This classification remains clinically relevant because response rates to subsequent platinum rechallenge generally correlate with the duration of the platinum-free interval.

Patients with partially platinum-sensitive disease often represent a therapeutic challenge because they may derive benefit from platinum rechallenge while simultaneously facing increased risk of cumulative toxicity or earlier resistance.

Trabectedin: Mechanism of Action

Trabectedin is a synthetic tetrahydroisoquinoline alkaloid originally isolated from the marine tunicate Ecteinascidia turbinata.

DNA Minor Groove Binding

Trabectedin binds covalently to guanine residues in the minor groove of DNA, producing bending of the DNA helix toward the major groove. This interaction interferes with transcription regulation and disrupts multiple cellular processes.

Interaction with DNA Repair Pathways

Trabectedin activity is closely linked to DNA repair mechanisms, particularly nucleotide excision repair (NER) and homologous recombination repair pathways. Preclinical studies have suggested increased sensitivity in tumors with homologous recombination deficiencies.

Tumor Microenvironment Effects

In addition to direct cytotoxic activity, trabectedin exerts effects on the tumor microenvironment. It has been shown to reduce inflammatory mediators and selectively affect tumor-associated macrophages, which may contribute to antitumor activity.

These combined mechanisms distinguish trabectedin from conventional platinum agents and taxanes.

Clinical Development in Ovarian Cancer

The OVA-301 Trial

The pivotal phase III OVA-301 trial evaluated:

• Trabectedin plus pegylated liposomal doxorubicin (PLD)
  versus
• PLD alone

in patients with recurrent ovarian cancer.

Study Outcomes

The study demonstrated improved progression-free survival (PFS) for the trabectedin plus PLD combination compared with PLD monotherapy.

In the overall study population:

• Median PFS was 7.3 months with trabectedin plus PLD
• Median PFS was 5.8 months with PLD alone

The greatest clinical benefit was observed in patients with platinum-sensitive and partially platinum-sensitive disease.

In the partially platinum-sensitive subgroup, the combination strategy supported the concept of extending the platinum-free interval before subsequent platinum rechallenge.

Longer overall survival trends were also observed in selected subgroups, particularly among patients with partially platinum-sensitive recurrence.

Therapeutic Rationale for Platinum-Free Interval Extension

Repeated platinum exposure may lead to:

• Cumulative peripheral neuropathy
• Hematologic toxicity
• Nephrotoxicity
• Ototoxicity
• Hypersensitivity reactions
• Progressive platinum resistance

The use of an effective non-platinum regimen such as trabectedin plus PLD may allow temporary postponement of further platinum exposure while maintaining disease control.

This therapeutic sequencing strategy may be particularly relevant in patients who:

• Previously responded to platinum therapy
• Require recovery from cumulative toxicities
• Develop platinum hypersensitivity reactions
• Need an alternative treatment interval before platinum rechallenge

Combination with Pegylated Liposomal Doxorubicin

The clinically established ovarian cancer regimen combines trabectedin with pegylated liposomal doxorubicin.

Clinical Rationale for Combination Therapy

PLD offers several clinical advantages, including:

• Activity in recurrent ovarian cancer
• Reduced cardiotoxicity compared with conventional doxorubicin
• Favorable tolerability profile
• Compatibility with platinum-sparing treatment approaches

The combination demonstrated improved efficacy compared with PLD alone and became an important therapeutic option for recurrent platinum-sensitive ovarian cancer.

Administration Considerations

Trabectedin is administered intravenously following PLD infusion, typically every 3 weeks.

Corticosteroid premedication with dexamethasone is routinely recommended because it:

• Reduces hepatotoxicity risk
• Provides antiemetic prophylaxis
• Improves treatment tolerability

Patients require monitoring of:

• Liver function tests
• Hematologic parameters
• Renal function
• Creatine phosphokinase (CPK)

Dose adjustments may be required depending on laboratory abnormalities and tolerability.

Safety and Tolerability

Trabectedin has a manageable but distinct toxicity profile.

Common Adverse Events

Frequently reported adverse events include:

• Neutropenia
• Elevated alanine aminotransferase (ALT)
• Elevated aspartate aminotransferase (AST)
• Fatigue
• Nausea
• Vomiting
• Anemia
• Thrombocytopenia

Transient elevations in liver enzymes are common and are generally reversible with appropriate monitoring and dose modification.

Serious Adverse Events

Less common but clinically important toxicities include:

• Febrile neutropenia
• Severe myelosuppression
• Severe hepatotoxicity
• Rhabdomyolysis

Careful patient selection, monitoring, and adherence to prescribing recommendations are essential.

Patient Selection

Trabectedin plus PLD may be considered in selected patients with:

• Platinum-sensitive recurrent ovarian cancer
• Partially platinum-sensitive disease
• Prior response to platinum therapy
• Need for platinum-free interval extension
• Cumulative platinum toxicities
• Platinum hypersensitivity reactions

Treatment decisions should remain individualized and consider:

• Prior lines of therapy
• Performance status
• Organ function
• Residual toxicities
• Patient preferences
• Treatment goals

Emerging Research and Future Directions

Ongoing research continues to evaluate the broader role of trabectedin in gynecologic oncology.

Areas under investigation include:

• Combination strategies with PARP inhibitors
• Biomarker-driven treatment selection
• Homologous recombination deficiency-related sensitivity
• Novel sequencing approaches
• Integration with immunotherapeutic strategies
• Further understanding of tumor microenvironment modulation

Although these approaches remain investigational, the unique biological properties of trabectedin continue to generate clinical interest.

Positioning in Modern Ovarian Cancer Management

The treatment landscape of ovarian cancer has evolved substantially with the introduction of:

• PARP inhibitors
• Antiangiogenic therapies
• Maintenance strategies
• Biomarker-guided treatment approaches

Despite these advances, chemotherapy remains a critical component of recurrent ovarian cancer management.

Trabectedin continues to provide value as:

• A non-platinum therapeutic option
• A treatment sequencing strategy
• A potential platinum-free interval extension approach
• An option for selected patients with partially platinum-sensitive disease

Its role is particularly relevant in individualized treatment planning where balancing efficacy, toxicity, and sequencing considerations is essential.

Conclusion

Trabectedin, in combination with pegylated liposomal doxorubicin, represents an important therapeutic option in recurrent platinum-sensitive ovarian cancer, particularly among patients with partially platinum-sensitive recurrence.

Its unique mechanism of action, including DNA minor groove binding and modulation of the tumor microenvironment, differentiates it from conventional chemotherapy agents and supports its use as part of platinum-sparing treatment strategies.

Clinical evidence from the OVA-301 trial demonstrated improved progression-free survival with trabectedin plus PLD compared with PLD alone, helping establish its role in recurrent disease management.

As ovarian cancer treatment continues to evolve toward increasingly personalized therapeutic approaches, trabectedin remains a relevant option for selected patients requiring individualized sequencing strategies and non-platinum alternatives.

Key Takeaways

• Trabectedin is a marine-derived antineoplastic agent with a unique mechanism of action.
• The combination of trabectedin and pegylated liposomal doxorubicin is an established option in recurrent platinum-sensitive ovarian cancer.
• Clinical benefit is particularly relevant in partially platinum-sensitive disease.
• Trabectedin-based therapy may support platinum-free interval extension strategies.
• Common toxicities include myelosuppression and transient liver enzyme elevations.
• Careful patient monitoring and individualized treatment selection are essential.
• Ongoing research is exploring biomarkers and novel combination strategies involving trabectedin.